Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01 ER 1504A, 01 ER 1504B, 01 ER 1504C)
Text and Data Mining valid from 2018-12-01
Received: 24 August 2018
Accepted: 11 November 2018
First Online: 13 December 2018
Ethics approval and consent to participate
: The study protocol was approved by the ethics committee of the Charité – Universitätsmedizin Berlin. Parents and patients from the age of 8 years gave their informed assent/consent for participation.
: Not applicable.
: C Sengler, none; J Zink, none; J Klotsche, none; M Niewerth, none; I Liedmann, none; G Horneff has received honoraria from Novartis, Chugai, Boeringer, Celgene and BMS and research grants from AbbVie, Chugai, MSD, Novartis, Pfizer and Roche; G Ganser, none; A Thon, none; J-P Haas has received research support from Novartis and Pfizer; A Hospach has received consulting fees, speaking fees and/or honoraria from Chugai and Novartis (< US$10,000 each); F Weller-Heinemann, none; A Heiligenhaus has received research grants from Pfizer and Novartis and honoraria from AbbVie, Alimera Sciences, Allergan, MSD Sharp and Dohme, Pfizer, Santen and Xoma; D Foell has received consulting fees, speaking fees and/or honoraria from Chugai-Roche, Sobi, Novartis and Pfizer (< US$10,000 each) and research grants from Novartis and Pfizer; Drs Kessel and Foell have submitted a patent application relating to the use of proinflammatory S100A12 homomultimers in the diagnosis and treatment of inflammatory disorders (WO 2016/178154 A1); A Zink, none; K Minden has received honoraria (< US$10.000) from AbbVie, Biermann, Chugai, Medac and Roche.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.